DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26 USD | -3.56% |
|
+29.16% | +150.00% |
| 06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
| 06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Press Releases